Drug recall · June 8, 2022
Anagrelide Capsules USP recall
Why: Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Anagrelide Capsules USP, 0.5 mg, 100-count bottles, Rx Only, Manufactured in India For: TEVA PHARMACEUTICALS USA, Inc., North Wales, PA 19454. NDC 0172-5241-60.
- Lots / codes
Lot # GD01090, Exp 05/2022
- Quantity
- 4224 cartons
- Company
- Teva Pharmaceuticals USA Inc, Parsippany, NJ
- Distribution
- Distributed Nationwide in the USA
- Initiated
- May 11, 2022 · Voluntary: Firm initiated
- Classified
- June 8, 2022
- Reported
- June 8, 2022
- Ended
- February 26, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Anagrelide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.